

Biotinylated Human GLP-1R Protein-Nanodisc



Cat. No. GLP-HM4N185BF


| | |
|------------------|--|
| Description | |
| Source | Recombinant Biotinylated Human GLP-1R Protein-Nanodisc is expressed from HEK293 with His tag and Avi tag at the C-terminus (FITC-equivalent protein is fused on cytoplasmic part). It contains Met1-Ser463. |
| Accession | P43220 |
| Molecular Weight | The protein has a predicted MW of 85.8 kDa. |
| Endotoxin | Less than 1EU per µg by the LAL method. |

| | |
|-------------------------|--|
| Formulation and Storage | |
| Formulation | Supplied as 0.22 µm filtered solution in PBS (pH 7.4). Notice: Not recommended for flow cytometry in mammalian cells. |
| Storage | Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |

| | |
|---|--|
| Background | |
| Glucagon-like peptide-1 receptor (GLP-1R) is a critical therapeutic target for type 2 diabetes mellitus (T2DM). GLP-1R emerged as an important pharmacological target for addressing T2DM, as it actively contributes to maintaining glucose homeostasis while promoting both β cell proliferation and insulin release. The impact of GLP-1R agonists such as semaglutide extends beyond diabetes control: they play a multifaceted role in regulating blood glucose levels by reducing hunger, moderating food intake, and managing body weight. Notably, GLP-1R agonists inhibit cancer progression in some malignant tumors. | |

| | |
|------------|--|
| Assay Data | |
| ELISA Data | |

Biotinylated Human GLP-1R Nanodisc, His Tag ELISA
0.5µg Biotinylated Human GLP-1R Nanodisc, His Tag Per Well



Immobilized Biotinylated Human GLP-1R Nanodisc, His Tag at 5µg/ml (100µl/well) on the streptavidin precoated plate (5µg/ml). Dose response curve for Anti-GLP-1R Antibody, hFc Tag with the EC50 of 0.28µg/ml determined by ELISA (QC Test).